Catalytic, Enantioselective N-Acylation of Lactams and Thiolactams Using Amidine-Based Catalysts
作者:Xing Yang、Valentina D. Bumbu、Peng Liu、Ximin Li、Hui Jiang、Eric W. Uffman、Lei Guo、Wei Zhang、Xuntian Jiang、K. N. Houk、Vladimir B. Birman
DOI:10.1021/ja306766n
日期:2012.10.24
contrast to alcohols and amines, racemic lactams and thiolactams cannot be resolved directly via enzymatic acylation or classical resolution. Asymmetric N-acylation promoted by amidine-based catalysts, particularly Cl-PIQ 2 and BTM 3, provides a convenient method for the kinetic resolution of these valuable compounds and often achieves excellent levels of enantioselectivity in this process. Density
[EN] CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MIMÉTIQUES DU CD4 EMPÊCHANT LA PÉNÉTRATION DU VIH-1 ET LEURS MÉTHODES D'UTILISATION
申请人:DANA FARBER CANCER INST INC
公开号:WO2013090696A1
公开(公告)日:2013-06-20
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gpl20, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD- 556.
Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization
作者:Judith M. LaLonde、Matthew Le-Khac、David M. Jones、Joel R. Courter、Jongwoo Park、Arne Schön、Amy M. Princiotto、Xueling Wu、John R. Mascola、Ernesto Freire、Joseph Sodroski、Navid Madani、Wayne A. Hendrickson、Amos B. Smith
DOI:10.1021/ml300407y
日期:2013.3.14
The design, synthesis, thermodynamic and crystallographic characterization of a potent, broad spectrum, second-generation HIV-1entryinhibitor that engages conserved carbonyl hydrogen bonds within gp120 has been achieved. The optimized antagonist exhibits a sub-micromolar binding affinity (110 nM) and inhibits viral entry of clade B and C viruses (IC50 geometric mean titer of 1.7 and 14.0 muM, respectively)
CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US20140350113A1
公开(公告)日:2014-11-27
Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.